Support solutions for patients who are uninsured or lack coverage for EYLEA

EYLEA4U® logo.
EYLEA4U® contact information.

Your patient may qualify for the PAP. Call your Reimbursement Business Manager or EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 4.

Visit the EYLEA4U e-Portal to learn

Patient eligibility criteria

  • Uninsured or lacks coverage for EYLEA
  • Must be a resident of the United States or its territories or possessions
  • Must have a completed EYLEA4U® Enrollment Form with patient signature in Section 6.3
  • Demonstrates financial need
    • Annual household adjusted gross income (AGI) must satisfy 1 of the following:
      • AGI is $100,000 or less
      • AGI is $100,001–$150,000 AND patient's out-of-pocket drug costs for EYLEA account for ≥3% of patient's AGI
        • Documentation of patient's out-of-pocket drug costs for EYLEA is required and can include:
          • Practice receipt of patient payment for EYLEA, which must include the amount paid specifically for EYLEA; practice billing record; or statements showing the patient’s EYLEA drug expenses have been billed

Patients are eligible for assistance for up to 1 year and must reapply annually.

EYLEA4U will independently verify a patient's income with our income validation tool.*

  • *If the income validation tool is unable to return results, the patient will be required by EYLEA4U to provide proof of income. Proof of income may also be requested at any time for audit/verification.

EYLEA4U Enrollment Form

Use the EYLEA4U Enrollment Form to request the specific
support your patients need, including copay assistance.

Patient assistance coverage

If a patient is determined to lack coverage for EYLEA through a payer denial and the denial is unsuccessfully appealed, the provider may qualify for a replacement EYLEA vial free of charge.

EYLEA4U is with you every step of the PAP process

Once the Enrollment Form requesting the PAP is received, a Reimbursement Specialist will:

Verify the patient's eligibility criteria and physician's decision to treat

Uninsured or lacks coverage for EYLEA

Is a resident of the United States or its territories or possessions

Demonstrates financial need
• Supporting documentation required

Notify you of patient's eligibility and, if approved, will:

Coordinate shipment of EYLEA to your practice

Send you a confirmation letter regarding patient enrollment, along with a Product Request Form (PRF) for future PAP shipments.
• Proactively send the PRF a week before the next scheduled injection to coordinate shipment

For questions about applying for coverage, PAP eligibility criteria, or denied claims, call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 4, Monday–Friday 9 AM–8 PM Eastern Time.

  • Because EYLEA is a physician-administered product with comprehensive insurance coverage, product may be administered to the patient prior to a determination of insurance coverage or eligibility for the PAP. If a patient is denied coverage, and if the denial is unsuccessfully appealed and the patient qualified for the PAP, EYLEA4U will provide the physician with a replacement vial free of charge. Subject to Regeneron policies.
Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
EYLEA news, events, and more.

Get the information you
and your patients need
about EYLEA.

See resources
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.